Therapy of malignant melanoma. First-, second- and pathogenesis-oriented third-line therapies;Therapie des metastasierten melanoms. First-, second- und pathogenese-orientierte third-line-therapien

Hautarzt

Volumn 57, Issue 9, 2006, Pages 773-784

  Rass, K ^a   Tadler, D ^a   Tilgen, W ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Chemotherapy; Malignant melanoma; Targeted therapy; Tumor surgery; Vaccination

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CPG OLIGODEOXYNUCLEOTIDE; DACARBAZINE; FOTEMUSTINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LOMUSTINE; SORAFENIB; TEMOZOLOMIDE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; HUMAN; IMMUNOTHERAPY; INOPERABLE CANCER; MELANOMA; METASTASIS; PALLIATIVE THERAPY; PATHOGENESIS; REVIEW;

ADJUVANTS, IMMUNOLOGIC; CANCER VACCINES; CHEMOTHERAPY, ADJUVANT; HUMANS; MELANOMA; PALLIATIVE CARE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; SKIN NEOPLASMS; TERMINAL CARE;

EID: 33748646950     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-006-1195-7     Document Type: Review

References (61)

1. Amiri KI, Horton LW, LaFleur BJ et al. (2004) Augmenting chemosensitivity of malignant melanoma tumours via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 64: 4912-4918
2. Ang KH, Peters LJ, Weber RS (1994) Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 30: 795-798
3. Attia P, Phan GQ, Maker AV et al. (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with Anti-Cytotoxic T-Lymphocyte Antigen-4. J Clin Oncol 23: 6043-6053
4. Avril MF, Aamdal S, Grob JJ et al.(2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase II study. J Clin Oncol 22: 1118-1125
5. Balch CM, Buzaid AC, Soong SJ et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648
6. Balch CM, Soong SJ, Gerschenwald JE et al. (2001) Prognostic factors analysis of 17.600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622-3634
7. Baldwin AS (2001) Control of oncogenesis and cancer therapy resistance by the transcription factor NF-.B. J Clin Invest 107: 241-246
8. Barranco S, Romsdahl M, Humphrey R (1971) The radiation response of human malignant melanoma cells grown in vitro. Cancer Res 31: 830
9. Becker JC, Schrama D, Bröcker EB, Houben R (2005) Kinaseinhibitoren zur Therapie des malignen Melanoms. J Dtsch Dermatol Ges 3: 762-767
10. Belardelli F, Ferrantini M, Parmiani G et al. (2004) International Meeting on Cancer Vaccines: How can we enhance efficacy of therapeutic vaccines? Cancer Res 64: 6827-6830
11. Buchsbaum JC, Shu JH, Lee SY et al. (2002) Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma. Cancer 94: 2265-2272
12. Chapman PB, Einhorn LH, Meyers ML et al. (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17: 2745-2751
13. Dalrymple-Hay MRJ, Rome PD, Kennedy C et al. (2002) Pulmonary metastatic melanoma - the survival benefit associated with positron emission tomography scanning. Eur J Cardiothorac Surg 21: 611-615
14. Danson S, Lorigan P, Arance A et al. (2003) A randomised study of temozolomide (TMZ) alone, with interferon (TMZ-IFN) or with thalidomide (TMZTHAL) in metastatic malignant melanoma. J Clin Oncol 21: 2551-2557
15. Danson S, Lorigan P (2005) Improving outcomes in advanced malignant melanoma - Update on systemic therapy. Drugs 65: 733-743
16. Davies H, Bignell GR, Cox C et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954
17. Dolan ME, Posner M, Karrison T et al. (2002) Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumours. Clin Cancer Res 8: 2519-2523
18. Dormond O, Foletti A, Paroz C, Rüegg C (2001) NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 7: 1041-1047
19. Eggermont AMM, Kirkwood JM (2004) Re-evaluating the role of dacarbazine in metastastic melanoma: what have we learned in 30 years? Eur J Cancer 40: 1825-1836
20. Eton O, Legha SS, Bedikian AY et al. (2002) Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20: 2045-2052
21. Flaherty KT, Brose M, Schuchter L et al. (2004) Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol 22: 708s
22. Garbe C, Eigentler TK (2004) Therapie des malignen Melanoms im Stadium der Fernmetastasierung. Hautarzt 55: 195-213
23. Garbe C, Hauschild A, Volkenandt M et al. (2005) Deutsche Leitlinie: Malignes Melanom, In: Garbe C (Hrsg) Interdisziplinäre Leitlinien zur Diagnostik und Behandlung von Hauttumoren. Thieme, Stuttgart, S 23-55
24. Helmbach H, Kern MA, Rossmann E et al. (2002) Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. J Invest Dermatol 118: 923-932
25. Hersey P, Sosman J, O'Day S et al. (2005) A phase II, randomized, open label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin +/- dacarbazine (DTIC) in patients with metastatic melanoma (MM). Proc Am Soc Clin Oncol, Abstract 7570
26. Hu Y, Cherton-Horvat G, Dragowska V et al. (2003) Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 9: 2826-2836
27. Huncharek M, Caubet JF, McGarry R (2001) Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 11: 75-81
28. Jansen B, Wacheck V, Heere-Ress E et al. (2000) Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356: 1728-1733
29. Kaufmann R, Spieth K, Leiter U et al. (2005) Temozolomide in combination with Interferon-alfa versus Temozolomide alone in patients with advanced metastatic melanoma: A randomized, Phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 23: 9001-9007
30. Kirova YM, Chen J, Rabarijaona LI et al. (1999) Radiotherapy as palliative treatment for metastatic melanoma. Melanoma Res 9: 611-613
31. Legha SS, Ring S, Bedikian T (1996) Treatment of metastastatic melanoma with combined chemotherapy containing cisplatin, vinblastin and dacarbazin (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 7: 827-825
32. Lejeune FL, Monnier Y, Rüegg C (2006) Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor. Melanoma Res 16: 263-265
33. Leo F, Cagini L, Rocmans P et al. (2000) Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer 83: 569-572
34. Lynch TJ, Bell DW, Sordella R et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139
35. Middleton MR, Grob JJ, Aaronson N et al. (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastastatic Melanoma. J Clin Oncol 18: 158-166
36. Middleton MR, Lee SM, Arance A et al. (2000) O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer 88: 469-473
37. Millward MJ, Bedikian AY, Conry RM et al. (2004) Randomised multinational phase 3 trial of dacarbazine with or without bcl-2 antisense (oblimersen sodium) in patients with advanced malignant melanoma [abstract No 7505]. Proc Am Soc Clin Oncol 22: 22
38. Morton DL (2001) Cytoreductive surgery and adjuvant immunotherapy in the management of metastatic melanoma. Tumori 87: 557-559
39. Peterson AC, Swiger S, Stadler WM et al. (2004) Phase II study of thr Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res 10: 4048-4054
40. Phan GQ, Yang J, Sherry RM et al. (2003) Cancer regression and autoimmunity induced by cytotoxic T-lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: 8372-8377
41. Plummer ER, Middleton MR, Lones C et al. (2005) Temozolomide pharmacodynamics in patients with metastastatic melanoma: DNA damage and activitiy of repair enzymes O6-alkylguanine alkyltransferase and Poly(ADP-ribose) polymerase-1. Clin Cancer Res 11: 3402-3409
42. Reinhold U, Hartl C, Hering R et al. (1997) Fatal rhabdomyolysis and multiple organ failure associated with adjuvant high-dose interferon alfa in malignant melanoma. Lancet 349: 540-541
43. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. (1998) Immunologic ant therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327
44. Schadendorf D, Ugurel S, Schuler-Thurner B et al. (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17: 563-570
45. Schneeder A, Wagner C, Zemann A et al. (2004) CpG motifs are efficient adjuvants for DNA vaccines. J Invest Dermatol 123: 371-379
46. Serrone L, Hersey P (1999) The chemoresistance of human malignant melanoma: an update. Melanoma Res 9: 51-58
47. Sosman JA, Unger JM, Liu PY et al. (2002) Adjuvant immunotherapy of resected, intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine, II: Impact of HLA class I antigen expression on outcome. J Clin Oncol 20: 2067-2075
48. Sosman JA, Weeraratna AT, Sondak VK (2004) When will melanoma vaccines be proven effective? J Clin Oncol 22: 387-389
49. Sosman JA, Puzaniv I (2006) Molecular targets in melanoma from angiogenesis to apoptosis. Clin Cancer Res 12 [7 Suppl]: 2376-2383
50. Stas M, Stroobants S, Dupont P et al. (2002) 18-FDG-PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res 12: 479-490
51. Strumberg D, Richly H, Hilger RA et al. (2005) Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients. J Clin Oncol 23: 965-972
52. Tagawa ST, Cheung E, Banta W et al. (2006) Survival Analysis after resection of metastatic disease followed by peptide vaccines in patients with stage IV melanoma. Cancer 106: 1353-1357
53. Tentori L, Leonetti C, Scarsella M et al. (2003) Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1-inhibitor, increases the antitumour activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 9: 5370-5379
54. Thompson JF, Scolyer RA, Kefford RF (2005) Cutaneous melanoma. Lancet 365: 687-701
55. Tilgen W, Rass K, Reichrath J (2005) 30 Jahre dermatologische Onkologie, In: Jung EG (Hrsg) 30 Jahre Aktuelle Dermatologie. Thieme, Stuttgart New York, S 88-98
56. Tilgen W, Uhl K, Bröcker EB (1997) Palliative Therapie des malignen Melanoms, In: Garbe C, Dummer R, Kaufmann R, Tilgen W (Hrsg) Dermatologische Onkologie. Springer, Berlin Heidelberg New York Tokyo, S 369-386
57. Tucker GC (2003) Alpha v integrin inhibitors and cancer therapy. Curr Opinion Investig Drugs 4: 722-731
58. Ugurel S, Tilgen W, Reinhold U (2003) Chemosensitivity testing in malignant melanoma, In: Reinhold U, Tilgen W (Hrsg) Chemosensitivity testing in oncology. Springer, Berlin Heidelberg New York Tokyo, S 81-92
59. Wilhelm SM, Carter C, Tang L et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res 6: 7099-7109
60. Wong SL, Coit DG (2004) Role of surgery in patients with stage IV melanoma. Curr Opin Oncol 16: 155-160
61. Wyman K, Atkins MB, Prieto V et al. (2006) Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma. Cancer 1006: 2005-2011